Hoe CRISPR de genêskunde flugger omskriuwt as regeljouwers folgje kinne
May 28, 2026 · Frisian News
Gene-editing company CRISPR Therapeutics has won approval for three treatments in two years, while regulatory agencies struggle to keep pace with the science. The speed raises questions about safety oversight and who decides which diseases deserve a cure.
FryskYn maart 2026 makke CRISPR Therapeutics de FDA-goedkarring bekend foar in nije geneditearjende terapy. Elk medisyn rjochtet him op in seldsume bloedsteurnis. It bedriuw wurdt no wurdearre op in hege merkwearde, foaral boud op de belofte dat CRISPR genetyske sykten oan de woartel genêze kin. Mar de fluchheid fan goedkarring ropt in drege fraach op: kin de FDA wier folgje wat der bart neidat pasjinten de klinyk ferlitten hawwe?
Regelsjouwers yn Amearika en Jeropa karden dizze terapyen goed op basis fan gegevens út fase 2-ûndersiken, net de gruttere fase 3-stúdzjes dy't gewoanlik de feilichheidsgegevens fan in medisyn fêstlizze. De FDA komprimearre beoardielingstidlinen signifikant. Regeljouwers hawwe erkend dat se terapyen goedkard hienen sûnder in folslein begryp fan alle mooglike off-target effekten, de sneden dy't de genetyske skjirre op de ferkearde plakken yn it genoom makket.
CRISPR Therapeutics bestege jild oan lobbying yn de Feriene Steaten, neffens federale publikaasjegegevens. It bedriuw sette eardere FDA-personiel yn tsjinst. Dit is net ûnwettich, mar it ropt in foar de hân lizzend punt op: de minsken dy't de regels skriuwe, ferlitte de regearing faak en wurkje foar de bedriuwen dy't se eartiids kontrolearren. De oantrún om rap te gean rint nei ûnderen. As in bedriuw foar pasjinten stiet mei seldsume sykten sûnder oare opsjes, fiele regeljouwers druk om earst ja te sizzen en dernei te sjen.
De goedkarringen litte ek in nauer probleem sjen. CRISPR Therapeutics rjochtet him op sikkelselanemie en bèta-thalassemie, beide faker foarkommend by Afrikaanske en Mediterrane befolkingsgroepen. Dochs skreaun de ûndersiken benammen wite pasjinten yn út rike lannen. CRISPR syn genêsmiddels berikke de riken. De earmen krije it parseberjocht.
Yntusken binne off-target effekten al by echte pasjinten opdûkt. Lykas skeptisy warskôgen, karden regeljouwers de terapy goed sûnder folsleine kennis fan wat it docht. De FDA kin de fluchheid fan de wittenskip net folgje omdat de wittenskip flugger beweecht as amtners lêze kinne. Dy kleau sil allinnich grutter wurde.
In March 2026, CRISPR Therapeutics announced the FDA approval of another gene-editing therapy. Each treatment targets a rare blood disorder. The company now trades at a high market value, built largely on the promise that CRISPR can fix genetic diseases at their root. But the speed of approval raises a hard question: can the FDA actually track what happens after patients leave the clinic?
Regulatory agencies in America and Europe approved these therapies based on data from Phase 2 trials, not the larger Phase 3 studies that typically anchor a drug's safety record. The FDA compressed review timelines significantly. Regulators have acknowledged approving therapies without a full understanding of all possible off-target effects, the cuts that the genetic scissors make in the wrong places of the genome.
CRISPR Therapeutics spent money on lobbying in the United States, according to federal disclosure records. The company employed former FDA staffers. This is not illegal, but it raises an obvious point: the people who write the rules often leave government and work for the companies they once watched. The incentive to move fast flows downhill. When a company faces rare-disease patients with no other options, regulators feel pressure to say yes first and watch second.
The approvals also reveal a narrower problem. CRISPR Therapeutics targets sickle cell disease and beta thalassemia, both more common in African and Mediterranean populations. Yet the trials enrolled mostly white patients in wealthy countries. CRISPR's cures reach the rich. The poor get the press release.
Meanwhile, off-target effects have already shown up in real patients. As skeptics warned, regulators approved the therapy without full knowledge of what it does. The FDA cannot follow the speed of the science because the science moves faster than bureaucrats can read. That gap will only widen.
Published May 28, 2026 · Frisian News · Ljouwert, Fryslân